Anixa Biosciences, Inc. (ANIX)
Anixa Biosciences, Inc. is a biotechnology company focused on the development of cancer immunotherapies and infectious disease vaccines. The company leverages its immuno-oncology platform to create targeted treatments aimed at improving patient outcomes, with a particular emphasis on cancer vaccines and therapies.
Company News
The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.
Anixa Biosciences, a biotechnology company, has announced a $5 million stock buyback program, signaling confidence in its financial health and future prospects.
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.